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Abstract 
BRCA1-associated protein-1 (BAP1) tumor predisposition syndrome (BAP1-TPDS) is a 
recently identified hereditary cancer syndrome and a rapidly developing area of medical 
research. Germline mutations in this tumor suppressor gene predispose families to the 
development of various malignancies. The molecular functions of the gene as well as the clinical 
phenotype of the syndrome are still being clarified. The aim of this study is to conduct a 
comprehensive review of all published research into BAP1-TPDS to more thoroughly delineate 
the clinical implications of germline BAP1 mutations. Current evidence suggests that germline 
BAP1 mutations predispose families to uveal melanoma, malignant mesothelioma, cutaneous 
melanoma, renal cell carcinoma, characteristic benign skin lesions, and possibly a range of other 
cancers as well. Some of these cancers tend to be more aggressive, have a propensity to 
metastasize, and onset earlier in life in patients with BAP1 mutations. Survival in these patients 
is significantly decreased. Although further research is necessary, this information can aid in the 
management, diagnoses, prognoses, and therapy of these patients and their families, and 
highlights the importance of genetic counseling. 
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CHAPTER 1: INTRODUCTION 
 Germline mutations in tumor suppressor genes are of special importance in the medical 
field as they often characterize hereditary cancer syndromes. The value in understanding the 
gene function and phenotypic spectrum of these genes lies in the ability to prevent cancer and 
improve prognoses in known high-risk families by way of additional preventative testing, early 
detection, and targeted therapy. Germline mutation in BRCA1-associated protein-1 (BAP1) 
underlies the recently identified tumor predisposition syndrome (BAP1-TPDS) OMIM 614327 
(1).  The major detective work originally identifying this hereditary cancer syndrome came 
simultaneously from three independent research groups, focused in the different disease areas of 
uveal melanoma (UM), mesothelioma (MMe), cutaneous melanoma (CM) and skin lesions (2-4).  
Shortly after this, renal cell carcinoma (RCC) was identified as a major cancer associated with 
the syndrome (5). An increasing number of patients and families with germline BAP1 mutations 
have been reported since.  
Despite the rapidly evolving literature, a complete understanding of the gene function and 
phenotypic spectrum of the gene has not yet been established. Researchers have approached the 
study of this gene from cancer-specific perspectives, rather than a collective BAP1 approach. 
Rather than studying the spectrum of cancers associated with BAP1, researchers have reported 
chance findings of BAP1 mutations in their field of study. As such, the results of this research are 
often difficult to use by clinicians. Geneticists and genetic counselors may not be on the lookout 
for the BAP1 gene when faced with characteristic BAP1 families. Further, providers may not 
have the information necessary to make management recommendations to families when faced 
with a chance finding of BAP1 mutation. The aim of this review is to compile all reported 
research into the BAP1 tumor predisposition syndrome and summarize the current evidence for 
the phenotype for the syndrome in addition to other important clinical characteristics. This will 
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help to establish counseling, testing, and management guidelines. statistics. Since there were a 
larger number of females reported in the literature, gender distribution statistics were adjusted 
based on a weighting methodology with the following equation: ((proportion of gender with 
cancer type in general population) / (proportion of gender in this cohort)) * (proportion of gender 
with cancer type out of total patients with cancer type in BAP1 carriers). 
CHAPTER 2: METHODOLOGY 
A literature review was conducted on all peer-reviewed articles on BAP1 and its 
Drosophila homolog, Calypso published through January 1, 2015. A search on PubMed was 
directed with the keywords “BRCA1 associated protein-1,” “BAP1,” and “Calypso.”  
Unpublished material was not included and selected articles were limited to English language. 
Seventy seven articles pertaining to the human BAP1 gene and its association with cancer were 
obtained. Of these, 25 articles described patients with germline BAP1 mutations. The articles 
were collated and data were extracted via an article-by-article systematic review. Online 
supplemental material was consulted if available. Data extracted from the review included 
clinical information, molecular testing results, and method of molecular analysis. All reported 
mutations were reviewed and updated to the current standard nomenclature. All data were 
analyzed and calculated by the authors to produce relevant statistics. 
CHAPTER 3: RESULTS 
3.1 Molecular Function of BAP1 
BAP1 was originally found to be a deubiquitinating protein, specifically in the carboxy-
terminus hydrolase subfamily, in 1998 (6). Ubiquitin is a small protein that has been found in 
almost all tissue types (ubiquitously) attached to proteins as a post-translational modification to 
mark them for degradation and/or suppress their expression. Deubiquitinases remove ubiquitin 
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via hydrolysis to return expression of these proteins to normal levels. When tumor suppressors 
are ubiquitinated their expression levels decrease, often-increasing cell proliferation and 
decreasing apoptosis rates, among other oncogenetic activities. Therefore, depending on their 
targets, deubiquitinases can act as tumor suppressors themselves. Although, earlier reports 
speculated that the BAP1 tumor suppressor function was through its deubiquitinating activity 
upon BRCA1, this was refuted and later studies have indicated that it is an independent tumor 
suppressor (7). Rather, BAP1 was found to interact with the BRCA1/BARD1 tumor suppressor 
heterodimer via the BRCA1 RING finger domain to regulate DNA damage response and cell 
cycle activities (8). 
 BAP1 has also been shown to be a tumor suppressor independently. Nuclear-localized 
BAP1 is upregulated and inhibits cell proliferation in BRCA1-deficient cells (7). RNAi for BAP1 
results in cell proliferation, supporting that BAP1 acts as a tumor suppressor in an independent 
fashion as well (9). Further, studies show that BAP1 acts as a coactivator of transcription by 
forming complexes with Host Cell Factor 1 (HCFC1) and Yin Yang 1 (YY1), among other 
coactivators including OGT, and FOXK1/2 (10). HCFC1 is known to advance the cell cycle at 
the G1/S phase by forming histone-modifying complexes. Given BAP1’s association with HCF1, 
it was suggested that BAP1 functions as a cell cycle regulator as well, specifically as a cell 
proliferation activator (11). A similar role for BAP1 was found with ASXL1; forming the 
Polycomb repressive deubiquitinase (PR-DUB) complex, involved in removing ubiquitin from 
H2A histones (12). This implies a wider and more nuanced role for BAP1 in cancer. Further, this 
suggests that BAP1 is itself regulated, possibly by a master regulator. BAP1 undergoes 
autodeubiquitination to avoid sequestration in the cytoplasm and enter the nucleus to regulate 
other genes, demonstrating that BAP1 regulates its own expression as well (13). 
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 BAP1 has also been implicated to function in DNA damage repair as it is phosphorylated 
and unbound from chromatin following UV-induced DNA damage and replicative stress (14). 
Eletr et al. implied three possible scenarios in its function. The first scenario involved replication 
or repair machinery being allowed access to DNA to fix the damage. The second scenario 
involved BAP1 activating transcription of DNA repair genes. Both of these scenarios repair 
DNA damage to prevent tumor formation. Lastly, it was also thought that BAP1 may be 
involved in inducing apoptotic signals in cells with severe DNA damage. This allows cells with 
heavy DNA damage that are susceptible to oncogenesis to undergo cell death before tumor 
formation. All of these scenarios show BAP1’s crucial role in cancer initiation or progression. 
BAP1 was found to be involved in DNA double stranded break repair in chicken DT40 cell lines 
through homologous recombination (15). Recently, germline mutations in BAP1 have been 
found to result in DNA double stranded break repair deficiencies (16). Thus BAP1 appears to 
play a vital and very broad role in cell proliferation and tumor suppression. 
3.2 Clinical Findings Reported in Families with Germline BAP1 Mutations 
While the full phenotype of BAP1 tumor predisposition syndrome has not been fully 
characterized, increased awareness and study involving the gene has resulted in new data. There 
have been a total of 51 families with 167 individuals reported to carry BAP1 mutations, found 
either by genetic testing or through obligate carrier status (see references below) (Table 1). Of 
the mutation carriers, 66 are male (40%), 93 are female (56%), and no gender information was 
reported for 8 patients. The data from reported cases suggests that hereditary cancers which are 
likely associated with BAP1 include UM, MMe of the pleura and peritoneum, CM, RCC, as well 
as characteristic benign cutaneous lesions referred to herein as atypical Spitz tumors (AST). UM 
is the most common cancer diagnosed in patients with germline BAP1 mutations with a total of 
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49 patients (29%) (2-5, 17-26). Fifty of the 51 families presented with one or more of the four 
main cancers (UM, MMe, CM, and RCC). In the remaining family, the proband with the 
truncating mutation, c. 214del, p. I72L*6, presented with AST and reported a family history of 
gastric cancer, but no other individual in the family was tested. It should be noted that not all 
reported cancers were confirmed by the authors. The Venn diagrams (Figure 1a, 1b, Figure 2) 
summarize the cancer histories reported in these families. While we tried to clarify the phenotype 
of BAP1-TPDS by comparing the frequency of cancers diagnosed in our cohort with the 
frequency of those cancers in the general population by the Surveillance, Epidemiology and End 
Results (SEER) database, this is an imperfect comparison as our cohort consists of patients 
reported throughout the world while SEER only tracks diagnoses in the United States. 
Tumor studies were also commonly conducted in both germline mutation carriers and in 
sporadic tumors. Biallelic inactivation in germline mutation carriers was commonly reported 
among tumors thought to be BAP1 related and is a strong indication that a particular tumor may 
have been caused by a gene mutation. Further, protein studies on tumors in mutation carriers also 
indicate lack of BAP1 protein expression, indicating loss of the wild-type allele. This also fits 
Knudson’s two hit model of tumor suppressors. Somatic BAP1 mutations and lack of BAP1 
protein expression have also been observed in sporadic tumors and implicate BAP1 involvement 
in the tumor.  
3.3 Common BAP1-TPDS Tumors 
3.31 Uveal Melanoma 
 UM, the most common ocular malignancy in adults, has been shown to be associated 
with both germline and somatic BAP1 mutations (Table 2). Forty nine (29%) of reported BAP1 
carriers have had a diagnosis of UM (2-5, 17-30). Twenty two (45%) were male, 25 (51%) were 
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female, and 2 patients did not have gender information reported. The incidence of UM in patients 
with germline BAP1 is much higher than the 5.1 diagnoses per million people in the general 
population, suggesting UM is a common feature of BAP1 (31). 
The earliest age of onset in a BAP1 carrier is reported in a UM at age 16 and there have 
been a total of 4 UMs diagnosed by age 20 (19, 21, 24, 28). In fact, the median age of onset is 
earlier in UM patients with germline BAP1 mutation (51 years, range 16 – 72) compared with the 
general population (62 years), suggesting that germline BAP1 mutations predispose to the cancer 
(32) 
Beyond epidemiologic data, there is good molecular evidence that UM is associated with 
the BAP1-TPDS. Genetic analysis of UM tumor tissue (DNA sequencing, microsatellite markers, 
or SNP analysis) has been performed in at least 7 patients with germline BAP1 mutations. This 
work showed loss-of-heterozygosity (LOH) or loss of expression of the wild type allele, adding 
further support for the inclusion of UM in the phenotypic spectrum of the BAP1-TPDS (2, 4, 17, 
19, 21, 24). 
Somatic mutations of BAP1 have also been widely reported in UM (Table 3). Seven out 
of 15 (47%) UM tumors in mouse models were found to have somatic mutations through DNA 
sequencing (33). Small interfering RNA (siRNA) knockout of BAP1 in 3 human UM cell lines 
induced a stem-cell like phenotype in melanoma cells and decreased cell proliferation, 
suggesting that BAP1 functions in a manner uncharacteristic of traditional tumor suppressors 
(34). Further, 153 out of 725 (21%) human UM tumors tested via tumor sequencing showed 
somatic mutations in BAP1 (4, 17, 35-39). Koopmans et al. showed these somatic mutations 
were also correlated with a lack of BAP1 protein expression in the tumor as 30 of 35 (86%) 
tumors with somatic mutations also lacked BAP1 staining by immunohistochemistry (38). In 
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addition, a total of 73 out of 174 (42%) other UM tumors have lacked BAP1 expression upon 
immunohistochemistry (38, 40-42). This makes UM the most firmly established cancer type in 
BAP1 tumor predisposition syndrome. 
3.32 Malignant Mesothelioma 
 MMe can be diagnosed in multiple sites, most commonly the pleural lining of the lung, 
but also in the peritoneum. Both sites have been implicated in germline BAP1 carriers. A total of 
39 patients (23%) with germline mutations have been diagnosed with MMe (2-5, 19, 22, 26, 29, 
30, 43, 44). Twenty six patients (67%) were reported to have pleural MMe, 12 patients (31%) 
had peritoneal MMe, and 1 patient had diagnoses of both pleural and peritoneal MMe. Twelve  
(31%) of these patients are male and 27 (69%) patients are female. Interestingly, all 13 patients 
reported to have diagnoses of peritoneal MMe are female, while peritoneal MMe is slightly more 
commonly diagnosed in males (45). 
Another finding in this subset of patients is the high frequency of multiple cancers. 
Excluding cases of multiple MMe, 14 patients (36%) have been diagnosed with another primary 
cancer in addition to MMe. Of the second cancers, the co-occurrence of UM and MMe is a 
strong indicator of the BAP1-TPDS. The diagnosis of UM occurred in 5/39 (13%) of the MMe 
patients with a germline BAP1 mutation. In addition, Testa et al. found only 2 of 26 tested 
sporadic MMe patients with asbestos exposure carried germline BAP1 mutations. Upon further 
analysis it was determined those were the only two patients in the cohort with prior diagnoses of 
UM (3).  
Similar to the earlier onset of UM, the median age of diagnosis for MMe among the 
germline BAP1 mutation carriers was 56 (range 34 – 85) years, which is much earlier than onset 
in the general population (74 years) (46).  
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Studies on MMe tumor tissue from patients with germline BAP1 mutation add further 
support for the cancer type to be included in the spectrum of cancers associated with BAP1 
mutations. MMe tumors from 7 germline BAP1 mutation carriers have been shown to have loss 
of the wild type BAP1 allele or its expression as seen via tumor DNA sequencing, array-
comparative genomic hybridization, and/or absent staining for BAP1 via immunohistochemistry 
(3, 44). 
Asbestos exposure is a strong predisposing factor for MMe development in the general 
population, and an interaction with germline BAP1 mutation might result in an additive or 
synergistic effect. Testa et al. detected asbestos traces in homes of all affected family members in 
both of the families they report with germline mutations (3). Interestingly, Arzt et al. found no 
statistically significant effect of asbestos exposure on BAP1 protein expression and any potential 
mechanism of how asbestos and BAP1 may interact is unknown (47).  
 Somatic BAP1 mutations have also been reported in presumably sporadic MMe (Table 
3). A total of 162 of 406 (40%) MMe tumors were found to have BAP1 mutations via tumor 
DNA sequencing (3, 48-52). Of these, 14 tumors (5%) had biallelic BAP1 mutations (49). In 
addition, 156 of 314 (50%) MMe cell lines or tumor tissues lacked BAP1 expression by 
immunohistochemistry (3, 43, 47-49, 52, 53). Sequencing of MMe cell lines and fluorescence in-
situ hybridization (FISH) analysis showed somatic mutations in BAP1 in 10 of 30 (33%) lines 
and loss of BAP1 in 6 of 25 (24%) lines tested, respectively (48, 49). 
3.33 Cutaneous Melanoma 
CM is a common skin malignancy in the general population. Although CDKN2A 
mutations are a common factor in familial CM, BAP1 is also a likely contributor to hereditary 
CM. There are 23 (14%) reported patients with CM diagnoses out of a total of 167 patients with 
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germline BAP1 mutations (2, 4, 5, 18, 21). Thirteen (57%) reported patients are male and 10 
(43%) are female. The median age of diagnosis in BAP1 patients is 46 (range 25 – 72) years, 
much earlier than in the general population which is estimated at a median of 58 years (54). 
Notably, five (22%) of these patients have had multiple diagnoses of CM with a maximum of 7 
melanomas in a single patient (5, 18, 19). Further, 11 (48%) have had CM diagnosed in addition 
to another cancer (4, 5, 18, 29, 30, 44). Tumors from 4 of these patients show LOH and/or loss of 
expression of BAP1 via DNA sequencing, array-based comparative genomic hybridization, and 
negative staining by immunohistochemistry (4, 18, 44). Njauw et al. noted three families 
carrying germline mutations had diagnoses of nevoid type CM, a particularly rare subtype. 
Follow-up of these tumors revealed they were characterized by distinctly semitransluscent 
orange-red pigmentation and had high levels of Ki67 staining. These lesions were distinct from 
traditional CMs and may be related to AST (18).  
Somatic mutations in CM have also been noted in patients without germline mutation, 
indicating BAP1 may be involved in the pathogenesis of the malignancy (Table 3). A total of 3 of 
60 (5%) tumors were found to have somatic BAP1 mutations and 11 of 238 (5%) tumors were 
found to lack BAP1 staining by immunohistochemistry (4, 55, 56). This data indicates BAP1 
may be involved in the pathogenesis of the malignancy. 
3.34 Renal Cell Carcinoma 
Clear cell RCC is the most common primary malignancy of the kidney in the general 
population. Recently strong data suggesting a correlation between RCC and BAP1 has been 
published (Table 2). Seventeen (10%) BAP1 patients have been reported with RCC out of 167 
total patients with germline BAP1 mutations (3, 5, 18, 26, 57, 58). Seven (50%) reported patients 
are male, 7 (50%) female, and 3 reported cases did not include gender. The median age of onset 
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for RCC among BAP1 carriers is 47 (range 36-72) years, which is much earlier than in the 
general population, (64 years) (54). 
Tumor tissue studies in these patients also support the inclusion of RCC in the spectrum 
of tumors caused by BAP1. A total of six tumors in five of these germline patients were tested 
via SNP arrays, tumor DNA sequencing, and/or immunohistochemistry and all were found to 
have LOH or loss of protein expression in the tumor (5, 57).  
Somatic studies on RCC tumors also support an association (Table 3). A total of 249 of 
2483 (10%) renal tumors studied by tumor DNA sequencing or whole exome sequencing were 
found to carry somatic BAP1 mutations, while 273 out of 2343 (12%) tumors studied by 
immunohistochemistry had no BAP1 expression  
3.35 Cutaneous Melanocytic Lesions 
BAP1-TPDS is associated with a distinct subset of benign skin lesions located on the skin 
of the head and neck, trunk and limbs. There has been a range of names given to these, including 
melanocytic BAP1-mutated atypical intradermal tumors (MBAITs), AST and nevi, Wiesner nevi, 
and nevoid melanoma-like melanocytic proliferations (NEMMPs), but will be referred to herein 
as AST as these lesions fit closest clinically and pathologically to this designation, though they 
constitute a distinct subgroup (18, 59-61). These lesions are well-circumscribed dome shaped, 
skin-colored or reddish-brown nodules with average size of 5 mm. They widely range in number 
in patients and in different family members. Morphologically, the lesions are mostly located 
intradermal with occasional cases of involvement of the junctional epidermis and show 
cytological features resembling atypical Spitz nevi (62). These lesions are characterized by 
biallelic inactivation of BAP1 and frequent BRAFV600E mutation and both can be reliable markers 
for aiding in the diagnosis (61). 
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The prevalence of AST in BAP1-TPDS is unclear as in the majority of reported patients, 
these lesions were not carefully assessed. Out of 43 germline BAP1 patients where these lesions 
were assessed there have been a total of 31 patients (72%) with AST (4, 18, 19, 21, 25, 27, 30, 
44, 59). At least 11/31 (35%) of these patients had multiple lesions, with a range of 2 to more 
than 50 (4, 5, 18, 27, 29, 44). The median age of diagnosis of AST in germline BAP1 carriers 
was 42 years old. However, the median age of onset may actually be much younger due to the 
difficulty of diagnosis. Although their natural history is unknown, Busam et al. found AST to be 
present since childhood in one germline BAP1 mutation carrier (27, 63). Fourteen/31 (45%) of 
these patients have been diagnosed with cancer in addition to AST (4, 5, 18, 21, 29, 30, 44). 
Loss-of heterozygosity in the tumor was confirmed in 22 neoplasms in 3 germline mutation 
carriers from one family (4).  
Lesions with similar morphological and molecular alterations were also reported in patients 
with no germline BAP1 mutation (4, 56, 61, 63-67). Given the unique clinical, morphological 
and molecular characterization of these subtype of AST and the high frequency of these lesions 
in patients with germline BAP1 mutation it is highly recommended that ASTs in particular those 
with a prominent epithelioid component be screened for BAP1 status by immunohistochemistry. 
If BAP1 loss is detected, referral for genetic counseling and germline BAP1 testing should be 
considered (55). 
3.4 Uncommon BAP1-TPDS Tumors 
3.41 Basal Cell Carcinoma 
Eleven germline BAP1 mutation carriers from seven unrelated families had BCC (7%) 
(Table 2) (3, 24, 29, 30). Seven of these 11 (64%) patients presented with more than one tumor, 
with one patient presenting with 13 tumors.  Immunostaining revealed complete or partial loss of 
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BAP1 protein in all of the 19 tested tumors from two patients with germline BAP1 mutations but 
in none of the 22 tumors from individuals with no germline BAP1 mutation (29).  Thus, although 
there is a high incidence of BCC in the general population and the strong association with sun 
exposure makes it difficult to assess a possible association, the biallelic inactivation of BAP1 in 
BCC tumors from a subset of patients with germline BAP1 mutation suggests that BCC may be a 
feature of the BAP1-TPDS phenotype.  
3.42 Breast Cancer 
 BAP1’s role in hereditary breast cancer has been suspected, given its interaction with the 
breast cancer tumor suppressor BRCA1. However, data are somewhat conflicting as to whether 
breast cancer is part of the BAP1 tumor predisposition syndrome (Table 1). There are a total of 
9/93 (10%) of the female patients with BAP1 germline mutations with diagnoses of breast 
cancer, including a newly tested member of a previously reported family, (FUM104, IV.1) (3, 5, 
18, 19, 26, 30). One of these patients has had bilateral breast cancer (5). This is slightly lower 
than the approximately 12.3% risk of  developing breast cancer for women in the general 
population (54). However, since this is compared to a quoted lifetime risk, the proportion of 
BAP1 carriers with breast cancer may also grow as germline BAP1 mutation carriers from our 
cohort may very well develop breast cancer in the future. The median age of onset based on ages 
reported for 5 of these patients is 58 years (range 37 – 85), while 2 of these patients (including 
the patient with bilateral breast cancer) are only reported as “early onset”. Molecular studies on 
tumor tissue were performed on two of these patients using tumor DNA sequencing and 
immunohistochemistry. These tests showed loss of the wild type allele and loss of BAP1 staining 
indicating biallelic inactivation (5). However, germline BAP1 mutations are not common in 
breast cancer despite family histories consistent with a TPDS. For example, studies have shown 
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only two synonymous, non-truncating germline BAP1 variants and no truncating mutations in a 
total of 330 breast cancer patients with high predisposition to breast cancer, including 143 
patients who tested negative for mutations in the traditional breast cancer predisposition genes, 
BRCA1 and 2 (5, 68, 69). Somatic studies have also shown a lack of association between BAP1 
and breast cancer (70) (Table 3). Je et al. found no somatic BAP1 mutations in breast cancers 
from 45 Korean patients without germline mutations. Thus, while rates of breast cancer may be 
elevated in patients with germline BAP1 mutation, the finding of BAP1 mutation in breast cancer 
is rare and more research must be conducted to clarify the association of BAP1 mutation and 
breast cancer. It should be noted that BAP1 has been recently added to some of the multigene 
panels offered by several clinical laboratories including those for breast cancers.   
3.43 Lung Carcinoma 
There have been 6 reported cases (4%) of lung adenocarcinoma in germline BAP1 
mutation carriers and no reports of small cell or squamous cell carcinoma (2, 18, 19, 24). There 
were no reports on the patients’ smoking status. Tumor testing revealed LOH in one of these 
tumors as well as lack of BAP1 staining by immunohistochemistry (2). Somatic studies of BAP1 
in unselected lung cancer found a low mutation rate as Jensen et al. found 1 somatic mutation of 
44 (2%) small-cell lung cancer tissues tested, and 1 somatic mutation of 33 (3%) non-small cell 
lung cancers tested (6). However, lung cancer cell lines in mice were found to have an increase 
in tumorigenicity after BAP1 knockout (7).  Further, immunostaining showed a high rate of 
BAP1 loss in lung adenocarcinoma compared with squamous cell carcinoma (78% vs 46%) and 
there was a significant association between BAP1 loss and histological type as well as tumor 
aggressiveness (71).  This suggests that in lung cancer, mechanisms other than direct gene 
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mutation play a crucial role in BAP1 protein loss. Further studies are needed to assess the 
possible association of BAP1-TPDS with lung adenocarcinoma.   
3.44 Cholangiocarcinoma 
 Cholangiocarcinoma is a rare, particularly aggressive form of cancer and evidence for its 
association with BAP1 is growing (Table 2). There have been only four patients (2%) with 
germline mutations diagnosed with cholangiocarcinoma (18, 25, 26, 30). However, low survival 
rates may mean patients diagnosed with cholangiocarcinoma are not tested, possibly deflating 
carrier statistics. Unfortunately, tumor studies were only done for one of these patients, which 
showed that the metastatic cholangiocarcinoma retained the wild type allele as seen by tumor 
DNA sequencing, but the tumor showed loss of nuclear localization of BAP1 (26). Among 
presumably sporadic patients, there have been a total of 32 cholangiocarcinoma tumors that were 
found to have somatic BAP1 mutations out of a total of 283 tumors studied (11%) via tumor 
DNA and Next-Generation Sequencing (72-74). This may indicate that BAP1 is involved in the 
tumorigenesis of cholangiocarcinoma (72-76) (Table 3).  
3.45 Meningioma 
Two patients presenting with meningioma were found to carry BAP1 mutations and for 
one of these patients a second-degree relative also had a meningioma, but was not tested for 
BAP1 (2, 29). Tumor studies were conducted for one of these patients and biallelic inactivation 
of BAP1 was confirmed through lack of BAP1 staining via immunohistochemistry. Though 
malignant meningiomas occur infrequently, pathological examination of a metastatic tumor from 
the other patient with a germline BAP1 mutation suggested that the primary tumor was a 
papillary meningioma (30).  
3.46 Other Tumors 
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  A number of other tumor types that have been reported in germline BAP1 mutation 
carriers; however there is a limited amount of data supporting their inclusion in BAP1-TPDS and 
continued research is needed (Table 1).  
 There have been 3 reported diagnoses (2%) of non-specific abdominal carcinomas among 
germline BAP1 mutation carriers, one of which was felt to be an ovarian cancer by the authors 
(2, 24, 26). Three patients (3% of females) with germline BAP1 mutations have been diagnosed 
with ovarian cancer, including a newly tested patient from a family previously reported by our 
group (FUM104, III.8) (2, 3, 26). There have been single patients with germline BAP1 mutations 
with diagnoses of cervical cancer, unspecified pancreatic cancer, squamous cell carcinoma, 
unspecified thyroid cancer, and urothelial (transitional cell) carcinoma; however no tumor tissue 
was available to confirm BAP1 involvement (3, 5, 25). The mutation carrier diagnosed with 
urothelial (transitional cell) carcinoma was also diagnosed with UM with liver metastasis (25). 
There have been a few germline mutation carriers diagnosed with a range of sarcomas including 
leiomyosarcoma, malignant fibrous histiocytoma, spinal bone cancer, and spindle cell type soft 
tissue sarcoma (3, 19, 26). No tumor studies were conducted on the histiocytoma; however 
metastatic tissue from the same patient did not show somatic loss of the wild type allele in the 
tissue (19). Two germline mutation carriers presented with neuroendocrine cancers, including 
paraganglioma of the pericardium. Tumor studies from the paraganglioma tissue showed LOH 
via tumor DNA Sanger sequencing (19). 
One patient with a germline BAP1 mutation was diagnosed with a colorectal cancer, but 
no tumor was available for study (26). Somatic studies of BAP1 have also been done on 
unselected colorectal cancer cases, with inconsistent results: 1/45 tumors showed a somatic 
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mutation while 5/252 tumors showed loss of BAP1 staining and 127/260 tumors showed low 
staining (70, 77).  
There has been one patient with a germline BAP1 mutation that was diagnosed with a 
prostate cancer, though no tumor testing was done (21). In a cohort of Korean patients, Je et al. 
found no somatic BAP1 mutations in 45 prostate tumors using tumor DNA sequencing (70). 
Many of these tumor types occur frequently in the general population and it is possible 
they arose coincidentally in germline BAP1 mutation carriers. As such it is difficult to be certain 
these cancers are a feature of the BAP1 phenotype. 
3.5 Germline BAP1 Mutation and Tumor Aggressiveness 
There is evidence that patients with germline BAP1 mutations tend to have more 
aggressive cancers with higher tumor staging and a greater likelihood of metastasis. Germline 
mutation results in higher rates of metastasis in UM, especially to the liver, with  Njauw et al. 
finding 4 of 50 metastatic UM patients carried germline mutations as compared to 0 of 50 in a 
non-metastatic cohort (18). 
Tumors with somatic BAP1 mutations have also demonstrated larger tumor sizes, more 
aggressive disease with poorer oncological outcomes, and higher rates of metastasis (58, 78-80). 
Somatic BAP1 mutations are observed more frequently in the more aggressive “class 2” UM 
tumors (84%) as compared with the less aggressive “class 1” tumors (4%) (17). It was suggested 
that the single “class 1” tumor with a BAP1 somatic mutation in this study was in transition to 
becoming a “class 2” tumor, implicating BAP1 mutation as a precursor event to “class 2” tumor 
status. The five “class 2” tumors not found to have somatic mutations had low levels of BAP1 
mRNA expression, suggesting epigenetic inactivation. Somatic BAP1 mutations may also define 
a separate class of MMe tumors. de Reynies et al. found that somatic BAP1 mutations in MMe 
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were strongly connected with a new subset of epithelioid MMe defined as “class 1” by molecular 
profile, which showed better prognoses and higher mutation rates than “class 2” MMe. In their 
cohort of 104 tumors, 87% of class 1 MMe harbored somatic BAP1 mutations whereas only 37% 
of class 2 MMe had BAP1 mutations (50). These findings stand in contrast to UM, tumors in 
which the more aggressive tumors, designated “class 2” by gene expression profile had high 
frequency of somatic BAP1 mutation, epithelioid cell type, and worse disease prognosis. 
Interestingly, BAP1 mutations are characteristic of epithelioid morphology in both UM and 
MMe. BAP1 mutations seem to characterize different classes of tumors in CM as well. Murali et 
al. found that absent staining for BAP1 by immunohistochemistry was seen more frequently in 
desmoplastic melanomas (22%) than in other CM subtypes (3%) (55). It is possible that BAP1 
loss is a feature inherent to desmoplastic melanomas specifically (81). Similar findings were 
reported in RCC as Pena-Llopis et al. showed RCC tissues rarely harbored coexisting somatic 
BAP1 and PBRM1 mutations, but rather there was strong histological distinction in the tumors 
depending on the mutant gene (82). RCC tumor staging in patients with germline BAP1 
mutations was variable: 3 tumors were Fuhrman grade III, 4 tumors were grade II, 3 tumors were 
grade I-II, and 1 was grade I (5, 57).Characterization of separate classes of UM, MMe, CM and 
RCC tumors by mutational profile could provide valuable diagnostic and prognostic indicators 
for clinicians.  
Studies with regard to survival have also pointed to shorter survival in patients with 
tumors exhibiting somatic BAP1 mutations or lack of BAP1 expression. Tissue microarray 
(TMA) studies of primary UM showed mean survival in patients that did not have BAP1 protein 
expression was 4.74 years as compared to 9.97 years in patients with UM tumors with BAP1 
protein expression (41). In CM, tumors with low BAP1 expression tends to have poorer 
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outcomes; however BAP1 has also been seen to play a survival role in melanoma cells as BAP1 
depletion reduces proliferation and increases apoptosis rates while resuming metabolism of 
survivin (81). Similarly, Hakimi et al. found an average of 31.2 months survival in RCC patients 
with somatic BAP1 mutations as compared to 78.2 months survival in patients whose tumor 
tested wild type for BAP1 in a cohort of 421 patients (83). Kapur et al. determined similar 
survival rates with an average of 1.9 years survival in RCC patients with tumors with somatic 
BAP1 mutations versus 5.4 years survival in patients with tumors with PBRM1 mutations in a 
cohort of 327 patients (84). A second, smaller cohort of 145 patients in the study showed 4.6 
years survival in BAP1 mutant tumors versus 10.6 years survival in PBRM1 mutant tumors. 
In contrast to the data that germline BAP1 mutation portends a worse prognosis in UM, 
CM, and RCC, survival in patients with germline BAP1 mutations developing MMe suggest that 
these patients have longer overall survival as compared with sporadic MMe patients. Baumann et 
al. found 7-fold longer survival in a cohort of 23 mesothelioma patients with germline BAP1 
mutations. Patients with germline BAP1 mutation and peritoneal mesothelioma also exhibited 
improved survival as compared to patients with pleural mesothelioma (85). Long term survival 
and well-differentiated tumor histology were also observed in one of our patients with MMe 
(FUM064, III.12). Similar findings were reported in two patients from another family. The 
mutations reported in the two families with well-differentiated MMe were truncating, c. 
758_759insA, p. Gln253fs*31 and c. 2050C>T, p. Gln684*. The c. 2050C>T, p. Gln684* 
mutation was also carried by several other family members with aggressive cancers including 
UM, bone cancer, and abdominal cancer. The molecular mechanism of such variation in 
aggressiveness between MMe and other cancers such as UM, CM, and RCC is not clear. It has 
been suggested that these cancer cells are more susceptible to therapy. 
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3.6 Penetrance of BAP1-TPDS 
Current evidence suggests that the penetrance of BAP1 mutations is high with 153/167 
(92%) germline BAP1 mutation carriers affected with cancer (5, 18, 19, 21, 26). Although ages 
for unaffected individuals were not reported, estimates based on the pedigrees placed an average 
unaffected age in the late 50’s. However, it should be noted that several reported unaffected 
carriers are young and therefore may develop cancers in the future. One BAP1 patient (FUM036, 
III.9) previously reported to be unaffected by our group subsequently developed MMe at age 60 
and passed away (2). Additionally, two newly tested members of families previously reported by 
our group were found to carry the family mutations and remain unaffected at ages 47 and 35, 
respectively (FUM103, III.3; FUM152, III.2) (26, 28).  
It is likely, however, that these penetrance data are inflated by test bias since the patients 
and family members who get tested are generally those affected by cancer. Out of the 51 
reported families, in 25 only the affected proband was tested, and only 17 families had more than 
3 individuals tested. This selection bias inflates penetrance data and the true penetrance for BAP1 
mutations may well lie lower than that calculated from current reported cases. 
The average age of cancer onset in BAP1 mutation carriers is 50 years with a range of 16 
to 85 years. The earliest reported age was for UM (21). Benign cutaneous lesions, which are 
characterized by somatic BAP1 loss, were present since childhood in at least one patient (27, 63). 
The natural history of these lesions is unknown, however. Aside from MMe, the other BAP1 
tumors all exhibit a significantly earlier age of onset as compared to tumors arising in the general 
population, supporting BAP1’s role in cancer predisposition (Table 2). 
3.7 Genotype-Phenotype Correlation 
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Out of 51 families, 44 had unique mutations, two families had the c. 2050C>T, p. 
Gln684* mutation, 2 families had the c. 1882_1885delTCAC, p.Ser628Profs*8 mutation, while 
three families had the c. 178C>T, p. Arg60*mutation. Discussions between the authors 
concluded the families carrying the c. 2050C>T, p. Gln684*and c. 1882_1885delTCAC, p. 
Ser628Profs*8 mutations were unrelated. Discussions between the authors and further testing 
suggested that the two families from Denmark carrying the c. 178C>T, p. Arg60*mutation were 
related, whereas the family carrying the mutation from the United States was not (3, 18, 26, 30). 
This could indicate a possible founder mutation or mutational hotspots.  
The vast majority (34/48, 71%) of the reported mutations were truncating, 9 (19%) were 
missense mutations thought to be pathogenic, and 8 (17%) were splice-site variations. Five of the 
splice site variations also caused protein truncation. Thus 18% of the reported germline 
mutations are missense mutations and 76% cause protein truncation. All the truncating mutations 
were proximal to the location of the nuclear localizing regions of BAP1.  
With the exception of one patient, all reported pathogenic mutations in BAP1, including 
truncating, missense, and splice site mutations, were associated with at least one of the four 
cancers, UM, CM, RCC, and/or MMe, in the family (Figure 3). All four cancers were observed 
with all different classes of mutations. Taken together, the available data suggest no clear 
genotype-phenotype correlation between type or location of the mutation and the type of cancer 
in the patients.  
Aoude et al. reported an interesting family with seven individuals with UM and a splice 
site variant in BAP1, c.581-2A>G. The variant was predicted to cause splicing out of exon 8 
leading to a premature truncation, but the observed splice product was smaller than would be 
predicted. In addition, one of the four UM patients who were tested was negative for the variant. 
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Although the authors concluded that the BAP1 c.581-2A>G variant was deleterious and the non-
carrier member was a sporadic case of UM occurring within a hereditary family, it should be 
noted that a genome wide linkage analysis of the same family found linkage to chromosomal 
region 9q21 suggesting the existence of another candidate gene in that family (86). Hence, 
another plausible explanation of their observation is that the c.581-2A>G variant was unrelated 
or modulates the effect of an undiscovered gene predisposing to cancer in this family.  
CHAPTER 4: DISCUSSION 
4.1 Genetic Counseling and Patient Management 
 Since 125 of 167 (75%) reported patients with BAP1 mutations were diagnosed with UM, 
MMe, CM, RCC, and/or BAP1 deficient atypical Spitz tumors, and 93% of these families had at 
least two of these tumors in first or second degree relatives, we feel that genetic assessment and 
testing for BAP1 mutations should be considered in patients with personal or family histories of 
two or more of these tumors in first or second degree relatives (with the exclusion of families 
with only multiple CM cases). Though a recent article recommended BAP1 testing in families 
with 2 or more cases of CM diagnosed before age 75 in first or second degree relatives, we feel 
this is overly broad given the high frequency of CM in the general population and the low 
likelihood that these families carry BAP1 mutations (87). Further, Harbour et al. suggested 
testing guidelines be extended to include family histories of one UM and two or more primary 
cancers of any type (88). Once again, we feel this recommendation is overly broad as there is not 
sufficient evidence at this time supporting the involvement of other cancers of any type. Only 1 
out of 44 BAP1 mutation families with reports of family history presented with UM and other 
cancers that weren’t the common BAP1 tumors. Since only one family presented with only 2 
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cases of CM and no history of the other BAP1 cancers, 91% of reported families would have 
been detected with our suggested criteria.  
Families in which a germline BAP1 mutation is found should receive counseling 
regarding cancer risk management options and risks to family members. Testing of at-risk family 
members is indicated since the syndrome follows an autosomal dominant inheritance pattern and 
first degree relatives have a 50% risk of inheriting the mutation. Although evidence-based 
management recommendations have not been established, the cancer risks in these families 
cannot be ignored. As such, regular examinations to facilitate early diagnosis, and thereby 
improved prognosis, are necessary. Although the recommended ages to begin screening given 
below are based on currently reported ages of diagnoses, if an individual family has a member 
diagnosed at an even earlier age for a specific cancer, screening for that cancer should begin for 
other members of that family about five years before that age of diagnosis. 
Yearly ophthalmic screenings with dilated examination and ophthalmic imaging are 
recommended due to the high risk for development of UM. As the earliest reported case of UM 
in a BAP1 mutation carrier was diagnosed at age 16, we suggest that these ophthalmic screenings 
begin at age 11 and should be performed by an ocular oncologist. Any nevi detected should be 
monitored with imaging at least every 6 months and considered for early treatment, given the 
association of BAP1 mutation with elevated metastatic risk in UM. For patients with UM and 
germline BAP1 mutation, we recommend screening for metastasis similar to what is currently 
recommended for high-risk class 2 patients. This includes screening every 3-6 months with liver-
directed imaging (e.g., abdominal ultrasound, computed tomography (CT), or magnetic 
resonance imaging (MRI) which is most sensitive) since metastatic spread from UM is most 
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frequent to the liver. Additionally, we recommend pulmonary imaging by CT or chest X-ray 
every 6-12 months to detect pulmonary metastasis. 
Unfortunately, screening for MMe is difficult. According to the National Comprehensive 
Cancer Network (NCCN) guidelines, there is no data indicating that screening improves survival 
in MMe patients with asbestos exposure (89). Currently, it is unknown whether screening could 
impact patients with germline BAP1 mutation, particularly since nearly 1/4 of identified germline 
carriers developed MMe and since they may have lower grade disease.  Interestingly, Faig et al. 
report that survival is improving for peritoneal MMe, and possibly for pleural MMe patients to a 
lesser extent, and suggest that newer therapies play a role in this improvement (90). 
The radiological features of MMe include peritoneal/pleural thickening and effusion. 
Importantly, biomarker tests are in development to improve early detection for MMe (91, 92).   
Thus, although this field is in flux, we recommend that the risk for developing MMe 
should be discussed with patients so they are on the lookout for symptoms and they should have 
a yearly physical examination whether they have symptoms or not. It has been suggested that 
MRI exams can aid in diagnosing peritoneal MMe and it is possible that patients followed for 
our RCC screening guidelines can also be screened for any peritoneal MMe development 
simultaneously (93). CT and chest X-rays have also been used in screening programs for MMe, 
but as a word of caution, given the potential role of BAP1 in DNA repair pathways, frequent 
radiation-based imaging modalities should be avoided when possible in these patients (15, 16). 
BAP1 mutation carriers are at increased risk for the development of both CM as well as 
atypical melanocytic nevi. Thus we recommend yearly full body dermatological screenings 
beginning at age 20, which is five years before the earliest reported case of CM in a BAP1 
mutation carrier. This parallels recommendations for carriers of germline mutations in the 
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CDKN2A gene made by The International Melanoma Genetics Consortium. Carriers are also 
instructed to conduct self-skin examinations following the ABCDE characteristics of melanoma 
and to use sun protection (94, 95).  
Atypical Spitz tumors with BAP1 loss are characteristic in families with germline BAP1 
mutations and can be used as a diagnostic marker. As diagnosis of the AST found in BAP1-
TPDS cannot be made through clinical features alone, patients found to harbor atypical Spitz 
tumors upon dermatological screenings should receive immunohistochemical staining for BAP1 
and BRAF mutation testing through pathological examination, especially if the lesions carry a 
prominent epithelial component (55). Patients with atypical Spitz tumors with BAP1 loss should 
be referred for genetic counseling and germline BAP1 testing. 
Consensus screening recommendations for RCC in at-risk patients in the general 
population have not been established. However, germline mutations in the VHL gene have been 
found to contribute risk for development of RCC in patients with von Hippel-Lindau (VHL) 
disease. To manage risk for development of RCC in VHL, it has been recommended that patients 
undergo yearly abdominal ultrasound examinations as well as abdominal magnetic resonance 
imaging (MRI) every 2 years (96). Until further data are available to direct management, we 
recommend considering this screening protocol for patients with BAP1 mutations. Since the 
earliest reported RCC in BAP1-TPDS patients was at age 36 years we recommend starting the 
screening at age 31 years. 
4.2 Potential Adjuvant Therapy 
 Since BAP1 research is still in its early stages and clinical applications are only recently 
being explored, there are currently no FDA-approved targeted treatments for BAP1-driven 
malignancies. Intriguingly, however, preliminary attempts at discovering therapies have shown 
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modest success in UM. Landreville et al. performed in silico and in vitro screens for treating 
class 2 UM with BAP1 loss and found histone deacetylase (HDAC) inhibitors to have anti-tumor 
activity. Specifically, BAP1-depleted UM cell lines were found to halt proliferation and tumor 
growth when exposed to the HDAC inhibitors valproic acid (VPA), trichostatin A (TSA), and 
LBH-589. TSA and LBH-589 also increased apoptosis rates, while VPA-treated cells returned to 
a class 1 (less aggressive) gene expression profile, regaining melanocytic differentiation (97). 
Tumors that may respond to such therapy may be recognized through detection of diminished 
BAP1 protein or RNA levels in tumor tissue. Currently a phase II clinical trial (NCT01587352) 
is on-going utilizing vorinostat in treating patients with metastatic UM. It will be interesting to 
see the impact of this agent in the adjuvant setting. A recent United States provisional patent 
submission (62/014,594, SK2014-029) by the Memorial Sloan Kettering Cancer Center aims at 
adapting an EZH2 inhibitor therapy, which is being used in Phase I/II trials for non-Hodgkins 
lymphoma patients, towards patients with BAP1-deficient tumors. The rationale for this use lies 
in BAP1’s function in forming the PR-DUB complex with ASXL1 and deubiquitinating H2A. 
EZH2 is upregulated when H2A is aberrantly hyperubiquitinated, as is the case in BAP1 
mutation (98). EZH2 inhibitor therapy may restore EZH2 expression to normal levels. No data 
for the use of this therapy in BAP1-driven tumors have been published, however. 
4.3 Conclusions 
 UM, MMe, CM, RCC, and atypical Spitz tumors are clearly established as part of the 
phenotypic spectrum associated with germline BAP1 mutations. Although other cancers, in 
particular breast cancer, lung adenocarcinoma, and cholangiocarcinoma might be associated at 
low frequency, further studies are needed to fully define the clinical phenotype of the BAP1-
TPDS. Although UM, CM, and RCC tumors in patients with germline BAP1 mutations tend to 
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be more aggressive and have poorer oncologic outcomes, for unknown reasons patients with 
diagnoses of MMe tend to have longer survival. There appears to be no genotype-phenotype 
correlation with this syndrome, as mutations in all domains of the BAP1 gene have been seen in 
patients. Penetrance for the gene appears to be high, but ascertainment bias makes it difficult 
currently to establish accurate estimates of cancer risk. Nonetheless, increased screening is 
indicated, particularly for skin and eye cancers.
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CHAPTER 5: TABLES AND FIGURES 
5.1 Table 1 
Table 1: Personal and family cancer histories of all reported families with BAP1 mutations. 
Family/ 
Case 
Cancers in patients with 
BAP1 mutation (Age of 
diagnosis) 
Mutation Mutation 
Classification 
Other Reported 
Cancers/Features in 
untested family members 
Reference 
MM087 UM (53) c. 1318_1319insA 
p. Glu402fs*2 
Frameshift - 
Truncating 
N/A Harbour et al., 2010 (17) 
SP-002 MMe (55), UM, 
leiomyosarcoma 
c. 1717delC 
p. Leu573Trpfs*3  
Frameshift - 
Truncating 
N/A Testa et al., 2011 (3) 
SP-008 MMe (63), UM c. 1882_1885delTCAC 
p. Ser628Profs*8  
Frameshift - 
Truncating 
N/A Testa et al., 2011 (3) 
Family L MMe (50, 59, 63), UM, 
Non-melanoma Skin Ca, 
Pancreatic Ca  
c. 2050C>T 
p. Gln684* 
Truncating MMe, UM, Prostate Testa et al., 2011 (3) 
Carbone at al., 2012 (99) 
Family W  MMe (36, 44, 50, 58, 58), 
Ovarian Ca (59), RCC 
(57), Breast Ca (37) 
c. 438-2 A>G 
p. Pro147fs*48 
Splice Site – 
Frameshift - 
Truncating 
None Testa et al., 2011 (3) 
Carbone at al., 2012 (99) 
Family 1 UM (72), CM, AST (36, 
42) 
c. 1305delG 
p. Gln436Asnfs*135 
Frameshift - 
Truncating 
AST, Cervical Ca, Multiple 
Myeloma 
Weisner et al., 2011 (4) 
Weisner et al., 2012 (61) 
Family 2 UM (44), CM (38, 39, 
50), AST (31, 40, 62), 
Peritoneal MMe 
c. 2057-2A>G 
p. Met687Glufs*28 
Splice Site – 
Frameshift - 
Truncating 
AST Weisner et al, 2011 (4) 
Weisner et al., 2012 (61) 
Family 
FUM036 
 
 
UM (50, 52), CM (72), 
MMe (55, 75), 
Meningioma, Lung Ca 
(56), Neuroendocrine Ca 
(52), Abdominal 
Adenocarcinoma/Ovarian 
Ca? (69) 
c. 799C>T 
p. Gln267* 
 
Truncating UM, CM x2, MMe x2, 
RCC, Meningioma, 
Testicular Ca, Abdominal 
Ca x3, Esophagus Ca, 
Adrenal Gland Ca, CaSU 
Abdel-Rahman et al., 2011 (2) 
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2734 UM (58) c. 1899_1900ins5 
p. Ala634Glyfs*5 
Frameshift - 
Truncating 
CM, Bladder Ca Njauw  et al., 2012 (18) 
3101 UM (53) c. 1975A>G 
p. Lys659* 
Truncating UM, RCC Njauw  et al., 2012 (18) 
3123 UM (37) c. 1831_1834del4 
p. Glu611Argfs*5 
Frameshift - 
Truncating 
Uterine Ca Njauw  et al., 2012 (18) 
Fam562 CM (31, 37, 37, 34, 35, 
35, 38, 45), UM (62), 
RCC (46), Lung Ca (49), 
AST x11 
c. 706_707insG 
p. Asp236Glyfs*7 
Frameshift - 
Truncating 
None Njauw  et al., 2012 (18) 
Fam714 CM (45), AST c. 178C>T 
p. Arg60* 
Truncating CM, Lung Ca, CNS Tumor Njauw  et al., 2012 (18) 
Wadt et al., 2014 (30) 
Fam729 UM (51, 55, 57, 59), CM 
(36, 60), Lung Ca (57), 
AST, Cholangiocarcinoma 
(47), Breast Ca x2 
c. 1153C>T 
p. Arg385* 
Truncating Breast Ca Njauw  et al., 2012 (18) 
Family 3 MMe (34, 44), Peritoneal 
MMe (34, 63), AST 
c. 79delG  
p. Val27Cysfs*45 
Frameshift - 
Truncating 
MMe Weisner et al., 2012 (44) 
 RCC (70) c. 121G>A 
p. Gly41Ser 
Truncating RCC x3, Parotid Gland 
Carcinoma, Breast Ca x2, 
Lung Ca, Sarcoma x2, 
Adenocortical Carcinoma 
Pena-Llopis et al., 2012 (82) 
 UM (18, 46, 62), CM (27, 
27, 33), MMe (47), 
Peritoneal MMe (84), 
Lung Ca (46), 
Paraganglioma (42), 
Breast Ca (75), MFH (45) 
c. 1708C>G 
p. Leu570Val 
Missense 
(Cryptic 
Splice Site 
Donor) 
Prolactinoma Wadt et al., 2012 (100) 
 UM c. 1480_1481delGA 
p. D494fs 
Frameshift - 
Truncating 
N/A Aoude et al., 2012 (20) 
 UM c. 1806G>C 
p. E602D 
Missense N/A Aoude et al., 2012 (20) 
 UM (16, 39, 44), CM, c. 75insG Frameshift - None Hoiom et al., 2013 (21) 
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Prostate Ca (67), AST p. Lys25fs*43 Truncating 
 AST (21) c. 214del 
p. I72L*6 
Frameshift - 
Truncating 
Gastric Ca Busam et al., 2013 (27) 
 UM (57), Peritoneal MMe 
(44, 56) 
c. 758_759insA 
p. Gln253fs*31 
Frameshift - 
Truncating 
Peritoneal MMe Ribeiro et al., 2013 (22) 
A Adenocarcinoma of 
Unknown Primitive 
Tumor, Breast Ca x3, 
RCC (37, 39, 40, 47, 47), 
Cervical Ca, CaSU 
c. 277A>G 
p. Thr93Ala 
Missense 
(Splice Site 
Donor) 
Esophagus Ca x2, Head 
and Neck Carcinoma, Lung 
Ca, Breast Ca 
Popova et al., 2013 (5) 
B UM (35), RCC (36) c. 629dupT 
p. Met211Hisfs*32 
Frameshift - 
Truncating 
RCC x2, UM x2, Bone Ca Popova et al., 2013 (5) 
C UM (52, 53), MMe (41, 
59), RCC (50), Digestive 
Tract Ca (45) 
c. 1654delG 
p. Asp552Ilefs*19 
Frameshift - 
Truncating 
MMe, CaSU Popova et al., 2013 (5) 
D UM (48), CM (34), BCC 
(51) 
c. 437+1G>A Splice Site Lung Ca, RCC, UM x2 Popova et al., 2013 (5) 
E UM (44), Thyroid Ca (34) c. 219delT 
p. Asp73Glufs*5 
Frameshift - 
Truncating 
MMe x2, Thyroid Ca, 
Bladder Ca 
Popova et al., 2013 (5) 
F MMe (44) c. 670dupC 
p. His224Profs*19 
Frameshift - 
Truncating 
MMe Popova et al., 2013 (5) 
G UM (57), CM (29, 31, 34, 
49), RCC (36)  
c. 37+1delG Splice Site MMe Popova et al., 2013 (5) 
H MMe (62) c. 1647delT 
p. Val550Serfs*21 
Frameshift - 
Truncating 
MMe Popova et al., 2013 (5) 
I UM (44) c. 1846delG 
p. Val616* 
Truncating CM Popova et al., 2013 (5) 
J UM (53), RCC (53) c. 78_79delG 
p. Val27Alafs*41 
Frameshift - 
Truncating 
RCC, MMe Popova et al., 2013 (5) 
K CM (47, 52), BCC (50) 
 
c. 660-11T>A Splice Site CM x2, MMe, RCC, UM Popova et al., 2013 (5) 
de la Fouchardier et al., 2014 
(29) 
L CM (47) c. 588G>A Splice Site - UM, Prostate Ca Popova et al., 2013 (5) 
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p. Trp196* Truncating 
NCI-1326 RCC (40, 44, 46, 54, 57) c. 41T>A 
p. L14H 
Missense RCC Farley et al., 2013 (57) 
 UM (40) c. 723T>G 
p. 241* 
Truncating UM, CM x3, MMe, Lung 
Ca x3, Colon Ca, Ovarian 
Ca, Gastric Ca x2 
Cheung et al., 2013 (23) 
 UM (20, 57, 69), CM 
(35), Lung Ca (59), 
Abdominal Ca (64), BCC 
x3 
c. 581-2A>G Splice Site UM x4, Breast Ca x2, 
Colon Ca, Non-melanoma 
Skin Ca, Lung Ca, 
Neuroendocrine Rectal Ca 
Aoude et al., 2013 (24) 
F4 RCC (56) c. 1946G>A 
p. C649Y 
Missense N/A Gossage et al., 2014 (58) 
A8 RCC (72) c. 851A>G 
p. E284G 
Missense N/A Gossage et al., 2014 (58) 
 UM (45, 56), 
Cholangiocarcinoma (71), 
Urothelial Carcinoma (48) 
c. 299T>C 
p. L100P 
Missense RCC, Brain Ca, Leukemia, 
Uterine Ca 
Maerker et al., 2014 (25) 
FUM064 UM (41, 49), Peritoneal 
MMe (48), Abdominal Ca 
(57), Bone Ca (64), Soft 
Tissue Carcinoma (42) 
c. 2050C>T 
p. Gln684* 
 
Truncating UM, MMe x2, RCC, 
CaSU, Pancreatic Ca, 
Papillary Thyroid Ca, 
Colorectal Ca, Breast Ca 
Pilarski et al., 2014 (26) 
FUM103 Cholangiocarcinoma c. 1182C>G 
p. Tyr394* 
Truncating Pancreactic Ca, Ovarian 
Ca, MMe, CaSU x2, Non-
melanoma Skin Ca 
Pilarski et al., 2014 (26) 
FUM104 UM (49, 67), RCC (47, 
49),  MMe (44), 
Peritoneal MMe (85), 
Breast Ca (58, 85), Colon 
Ca (71), Ovarian Ca (34) 
c. 1882_1885delTCA 
p. Ser628Profs*8 
Frameshift - 
Truncating 
RCC x3, MMe x2, Lung 
Ca x2, Breast Ca x2, 
Hematological Ca, Bladder 
Ca, Pancreatic Ca 
Pilarski et al., 2014 (26) 
Family 1 CM (60), Breast Ca (54), 
CaSU (pathologies point 
to Cholangiocarcinoma 
and Meningioma) (52, 55, 
c. 1209_1210dupT 
p. D404* 
Truncating CaSU, CM, Breast Ca Wadt et al., 2014 (30) 
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66), MMe (51, 62), 
Peritoneal MMe (46), 
Basal Cell Carcinoma 
(50), AST (32) 
Family 2 CM (55), Peritoneal MMe 
(56), AST (45) 
c. 838C>T 
p. Q280* 
Truncating UM, CM x2, RCC, Brain 
Ca 
Wadt et al., 2014 (30) 
Family 3 UM (54), BCC (43, 43, 
65, 65-80), CM (25), AST 
(24) 
c. 178C>T 
p. R60* 
Truncating Ovarian Ca, Granulosa 
Cell Tumor, UM x2, CM 
Wadt et al., 2014 (30) 
Family 4 UM (50, 59), BCC (46, 
50) 
c. 178C>T 
p. R60* 
Truncating BCC, MMe Wadt et al., 2014 (30) 
Family A Peritoneal MMe (63),  
MMe (79), 
Mucoepidermoid 
carcinoma (36) 
c. 46_47insA 
p. Thr16fs*52 
 
Frameshift - 
Truncating 
Hepatic Carcinoma,  MMe Betti et al., 2015 (43) 
FUM152 UM (18) c. 1717delC 
p. L573fs*3 
Frameshift - 
Truncating 
UM, CaSU Cebulla et al., 2015 (28)  
FUM124 UM (60), CM (72), MMe 
(71), BCC (56, 65, 68) 
c. 539T>C 
p. Leu180Pro 
Missense Breast Ca x2, BCC x6, 
SCC, Non-melanoma Skin 
Ca, CM x2, Prostate Ca, 
Uterine Ca, Liposarcoma, 
Melanoma (meningeal), 
Cervical Ca, CaSU x3, 
MMe, GI Tract Cancer 
Previously Unpublished OSU 
Family 
FUM128  Peritoneal MMe (60) c. 256-4_256-2del Splice Site – 
Frameshift - 
Truncating 
UM, MMe x3, Pancreatic 
Ca, Bladder Ca, 
Abdominal Ca, Ovarian Ca 
Previously Unpublished OSU 
Family 
UM, uveal melanoma; MMe, malignant mesothelioma; CM, cutaneous melanoma; RCC, renal cell carcinoma; AST, typical Spitz 
tumors; BCC, basal cell carcinoma; CaSU, cancer site unknown; CNS, central nervous system; MFH, malignant fibrocystic 
histiocytoma
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5.2 Table 2 
Table 2: Summary of cancers reported more than once in patients with germline BAP1 mutations. 
Tumor Type Frequency in germline 
BAP1 patients 
Lifetime 
risk of 
diagnosis in 
general 
population 
(percent) 
SEER+ (54) 
Median age of 
onset in 
germline BAP1 
patients (range) 
Median age of 
onset in 
general 
population 
(54)# 
Sex 
ratio 
M:F 
Biallelic inactivation 
shown in tumor* 
Uveal Melanoma 49/167 (2-5, 17-30) 0.00051% 
(31) 
51 (16-72) 62 (32) 22:25 Yes, 7 
(2, 4, 17, 19, 21, 24) 
Mesothelioma 39/167 
(2-5, 19, 22, 26, 29, 30, 
43, 44) 
0.13% 56 (34-85) 74 (46) 12:26 Yes, 7 (3, 44) 
Cutaneous 
Melanoma 
23/167 
(2, 4, 5, 18, 19, 21, 24, 29, 
30, 44) 
3.25% 46 (25-72) 58 12:10 Yes, 4 (4, 18, 44) 
Renal Cell 
Carcinoma 
17/167 
(3, 5, 18, 26, 57, 58, 82) 
1.60% 47 (36-72) 64 7:7 Yes, 5 (5, 57) 
Basal Cell 
Carcinoma 
11/167 
(3, 5, 24, 29, 30) 
- 50 (42-65) - 4:3 Yes, 3 (30) 
Breast Cancer 9/93 
(3, 5, 18, 19, 26, 30) 
12.33% 58 (37-85) 61 9 Yes, 2 (5) 
Lung Cancer 6/167 (2, 18, 19, 24) 6.99% 56 (46-59) 70 3:3 Yes, 1 (2) 
Cholangiocarcinoma 4/167 (18, 25, 26, 30) 0.89% 66 (47-71) 50 (101) 2:2 N/A 
Ovarian Cancer 3/93 (2, 3) 1.12% 59 (34-69) 63 3 N/A 
Meningioma 2/167 (2, 30) - 52    65 (102) 0:2 Yes, 1 (2) 
Abdominal Cancer 2/167 (24, 26) 0.86% 64 (57-64) 71 0:2 N/A 
*In patients with BAP1 germline mutation. 
+Age-adjusted SEER data from 2007-2011. 
#Age-adjusted SEER data from 2011. 
-SEER does not track epidemiological data for basal cell carcinoma and age of onset is generally not estimated in the literature. 
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5.3 Table 3 
Table 3: Studies demonstrating somatic BAP1 mutations and/or loss of expression in tumor cells.  
Tumor Type Cell Lines 
DNA  
Sequencing 
Cell Lines 
Fluorescence 
In-Situ 
Hybridization 
(FISH) 
Cell 
Lines 
IHC 
IHC Tumor DNA 
Sequencing 
Array 
Comparative 
Genomic 
Hybridization 
COSMIC 
Gene 
Expression 
(103) 
COSMIC 
Point 
Mutations 
(103) 
Uveal Melanoma    103/209 (38, 
40-42) 
153/725 (4, 17, 35-
39) 
  75/198 
Renal Cell 
Carcinoma 
   273/2343 (79, 
82, 104, 105) 
249/2483 (58, 78, 
80, 82-84, 106-109) 
 7/503 117/1673 
Cutaneous 
Melanoma 
   11/238 (55, 
56) 
3/60 (4)  2/336 34/904 
Mesothelioma 10/30     
(48, 49) 
6/25 (48) 8/13 
(3, 49) 
148/301 (43, 
47-49, 52, 53) 
162/406 (3, 48-52)   81/260 
Atypical Spitz 
Tumors 
   71/208 (56, 
61, 63-65, 67) 
15/104 (4, 63, 64, 
66, 67) 
29/436 (67)   
Bladder Cancer     8/54 (110)    
Breast Cancer     0/45 (70)  73/989 11/1653 
Cholangiocarcinoma     44/502 (72-76)  13/579 12/1154 
Gallbladder Cancer     2/42 (72, 74)    
Gastric Cancer     0/45 (70)  8/285 11/420 
Lung Cancer     2/77 (6)  51/865 13/1741 
Colorectal Cancer    5/252 (77) 1/45 (70)    
Pancreatic Cancer     1/23 (111)  2/70 5/1734 
Prostate Cancer     0/45 (70)  2/198 5/631 
Thymic Cancer     9/106 (112, 113)  2/494 2/529 
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5.4 Figure 1 
Figure 1. Venn diagram of the cancers identified in BAP1 patients and families 
A) Individuals with BAP1 mutations diagnosed with UM, RCC, CM, and/or MMe. Twenty eight individuals were 
only diagnosed with another cancer uncertain to be BAP1 related. Twelve individuals were diagnosed with atypical 
Spitz tumors only. Fourteen individuals were unaffected.  
B) Families with BAP1 mutations with mutation-positive members diagnosed with UM, RCC, CM, and MMe. One 
family presented with only atypical Spitz tumors and another cancer uncertain to be BAP1 related. One family did not 
have any members with UM, RCC, CM, or MMe tested. 
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5.5 Figure 2 
 
Figure 2: Families with germline BAP1 mutations with reported family histories of UM, RCC, CM, and MMe without being proven 
mutation carriers. One family is reported with only atypical Spitz tumors and another cancer uncertain to be BAP1 related. 
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5.6 Figure 3 
 
Figure 3: Gene location and mutation type of the reported germline pathogenic variants in BAP1 in the four main cancers associated 
with BAP1-TPDS. No genotype/phenotype correlation was observed. One family mutation (c. 214del, p. I72L*6) was found in a 
family not reporting a UM, RCC, CM, or MMe. One family mutation (c. 1182C>G, p. Tyr394*) was not tested in a member with a 
personal history of UM, RCC, CM, or MMe. 
UCH – Ubiquitin C-terminal hydrolase, BARD1 – BARD1 binding domain, HCF1 – HCF1 binding motif, BRCA1 – BRCA1 binding 
domain, N – Nuclear localization signal. 
[Red arrow – splice-site mutation;   Black arrow – truncating mutation;   Green arrow – missense mutation] 
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5.7 Figure 4 
 
Figure 4: Percentage of germline BAP1 mutation families with reported family history of UM, MMe, CM, or RCC. 
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